האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

biogaran - clopidogrel (as hydrogen sulfate) - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

ישראל - אנגלית - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - film coated tablets - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - secondary prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin; clopidogrel hydrogen sulfate -

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.9 mg - tablet - excipient ingredients: hyprolose; methylcellulose; iron oxide yellow; iron oxide red; purified water; zinc stearate; crospovidone; microcrystalline cellulose; maize starch; titanium dioxide; silicon dioxide; lactose; hypromellose; macrogol 8000 - this fixed dose combination product is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products:,? unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin 75/100 is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,? st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin 75/100 has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

accord healthcare limited - clopidogrel hydrogen sulphate - film-coated tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; clopidogrel

אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

splendris pharmaceuticals gmbh - clopidogrel hydrogen sulphate - film-coated tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; clopidogrel

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

teva pharma b.v.  - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

ישראל - אנגלית - Ministry of Health

padagis israel agencies ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

ישראל - אנגלית - Ministry of Health

dexcel ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 75 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

ישראל - אנגלית - Ministry of Health

dexcel ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.